Stockscreener 앱 받기
19.39
3.87%
0.745
시간 외 거래:
19.38
-0.005
-0.03%
전일 마감가:
$18.64
열려 있는:
$18.86
하루 거래량:
1.96M
Relative Volume:
1.13
시가총액:
$3.08B
수익:
$1.27M
순이익/손실:
$-512.54M
주가수익비율:
-6.5289
EPS:
-2.9691
순현금흐름:
$-422.10M
1주 성능:
+6.91%
1개월 성능:
-2.56%
6개월 성능:
-0.20%
1년 성능:
+44.27%
1일 변동 폭
$18.60
$19.63
1주일 범위
$18.11
$19.63
52주 변동 폭
$12.58
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
명칭
Denali Therapeutics Inc
전화
(650) 866-8547
주소
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
19.39 | 2.96B | 1.27M | -512.54M | -422.10M | -2.9691 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 재확인 | H.C. Wainwright | Buy |
| 2026-02-24 | 개시 | Wolfe Research | Peer Perform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-04-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 재개 | Morgan Stanley | Overweight |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2025-01-07 | 개시 | Robert W. Baird | Outperform |
| 2025-01-03 | 개시 | William Blair | Outperform |
| 2024-12-16 | 업그레이드 | Stifel | Hold → Buy |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-10-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 개시 | B. Riley Securities | Buy |
| 2023-01-30 | 개시 | SVB Securities | Outperform |
| 2022-12-05 | 개시 | Cowen | Outperform |
| 2022-11-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-02 | 개시 | BofA Securities | Buy |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-09-21 | 개시 | Oppenheimer | Outperform |
| 2021-09-01 | 개시 | SMBC Nikko | Outperform |
| 2021-05-18 | 개시 | UBS | Buy |
| 2021-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-02-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-02-24 | 개시 | Jefferies | Buy |
| 2020-02-19 | 개시 | Stifel | Hold |
| 2020-01-27 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-26 | 개시 | Wedbush | Neutral |
| 2019-09-13 | 개시 | Nomura | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 개시 | Janney | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 개시 | Goldman | Neutral |
| 2018-01-02 | 개시 | JP Morgan | Overweight |
| 2018-01-02 | 개시 | Morgan Stanley | Overweight |
모두보기
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says - marketscreener.com
Denali stock dips as Biogen-partnered Parkinson's disease study fails - MSN
Biogen and Denali discontinue Parkinson’s candidate BIIB122 after Phase IIb LUMA study miss - Manufacturing Chemist
Biogen, Denali to drop Parkinson’s therapy after mid-stage trial setback - MSN
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42 - Moomoo
Understanding the Setup: (DNLI) and Scalable Risk - Stock Traders Daily
Biogen (BIIB) and Denali (DNLI) Halt Development of BIIB122 Afte - GuruFocus
Is Early AVLAYAH Demand Reshaping The Investment Case For Denali Therapeutics’ Rare-Disease Platform (DNLI)? - Sahm
Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks - Yahoo Finance UK
Biogen and Denali Halt Development of BIIB122 After Phase 2b LUMA Study Fails in Early Parkinson’s Disease - Minichart
Morgan Stanley Cuts Price Target on Denali Therapeutics to $35 From $40, Keeps Overweight Rating - Moomoo
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails - Yahoo Finance
Deutsche Bank Adjusts Denali Therapeutics Price Target to $31 From $35, Maintains Buy Rating - Moomoo
Denali Therapeutics stock falls after Parkinson’s drug fails trial By Investing.com - Investing.com South Africa
Denali Therapeutics stock falls after Parkinson’s drug fails trial - Investing.com
H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Wedbush Cuts Price Target on Denali Therapeutics to $20 From $23, Keeps Outperform Rating - marketscreener.com
Biogen, Denali to drop Parkinson’s therapy (BIIB:NASDAQ) - Seeking Alpha
Parkinson’s drug from Biogen, Denali comes up short - Yahoo Finance
Denali Therapeutics and Biogen discontinue BIIB122 after Phase 2b LUMA misses endpoints - TradingView
Biogen, Denali scrap Parkinson’s candidate after Phase IIb miss - The Pharma Letter
DNLI Stock Price, Quote & Chart | DENALI THERAPEUTICS INC (NASDAQ:DNLI) - ChartMill
Biogen, Denali scrap Parkinson’s drug after failure in mid-to-late stage study - 1470 & 100.3 WMBD
Biogen, Denali discontinue Parkinson’s drug after trial fails By Investing.com - Investing.com Nigeria
Parkinson’s trial setback: Biogen, Denali halt BIIB122 program, await 2027 data - Stock Titan
Biogen and Denali Therapeutics Halt BIIB122 Development After Tr - GuruFocus
Biogen, Denali discontinue Parkinson’s drug after trial fails - Investing.com UK
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial - Yahoo Finance
Biogen (BIIB) Halts Development of BIIB122 After Phase 2b Study Results - GuruFocus
[8-K] Denali Therapeutics Inc. Reports Material Event - Stock Titan
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study - Reuters
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease - Biogen
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease - GlobeNewswire Inc.
Denali Therapeutics stock (US24823R1077): New data keeps biotech in focus - AD HOC NEWS
DNLI Q1 loss narrower than expected, Avlayah approval boosts prospects - MSN
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval - Yahoo Finance
DNLI gains 25.4% year to date: Should you buy, sell or hold the stock? - MSN
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval - sharewise.com
T. Rowe Price holds 5.4% of Denali Therapeutics (NASDAQ: DNLI) - Stock Titan
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate - BioSpace
FDA clears Denali Therapeutics drug as first brain-penetrating biologic for rare disease - MSN
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - The Manila Times
Morgan Stanley Trims Price Target on Denali Therapeutics to $40 From $42, Keeps Overweight Rating - Moomoo
Denali Therapeutics Inc (DNLI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.49%
0.12%
자본화:
|
볼륨(24시간):